
20/20 BioLabs
Total Raised
$16.47MInvestors Count
13Deal Terms
5Funding, Valuation & Revenue
22 Fundings
20/20 BioLabs has raised $16.47M over 22 rounds.
20/20 BioLabs's latest funding round was a IPO for on February 19, 2026.
20/20 BioLabs's 2024 revenue was $1.75M. 20/20 BioLabs's most recent revenue is from 2024.
Sign up for a free demo to see revenue data from 2024 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
2/19/2026 | IPO | 3 | ||||
12/13/2025 | Convertible Note - IV | $0.19M | PicMii | $1.75M FY 2024 | 1 | |
8/9/2025 | Convertible Note - III | $0.56M | PicMii | 1 | ||
2/25/2025 | Debt | |||||
2/1/2025 | Angel - III |
Date | 2/19/2026 | 12/13/2025 | 8/9/2025 | 2/25/2025 | 2/1/2025 |
|---|---|---|---|---|---|
Round | IPO | Convertible Note - IV | Convertible Note - III | Debt | Angel - III |
Amount | $0.19M | $0.56M | |||
Investors | PicMii | PicMii | |||
Valuation | |||||
Revenue | $1.75M FY 2024 | ||||
Sources | 3 | 1 | 1 |
20/20 BioLabs Deal Terms
5 Deal Terms
20/20 BioLabs's deal structure is available for 5 funding rounds, including their Convertible Note - II from December 16, 2022.
Round | Convertible Note - II | Angel - II | Series C | Angel | Series A |
|---|---|---|---|---|---|
Funding Date | |||||
Pre-Money Valuation | |||||
Post-Money Valuation | |||||
Amount Raised | |||||
Shares Authorized | |||||
Issuance Price | |||||
Dividend Rate | |||||
Liquidation Preferences | |||||
Liquidation Price | |||||
Participation | |||||
Conversion Price | |||||
Anti Dilution | |||||
General Voting | |||||
Board Voting | |||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Convertible Note - II | |||||||||||||||
Angel - II | |||||||||||||||
Series C | |||||||||||||||
Angel | |||||||||||||||
Series A |
20/20 BioLabs Investors
13 Investors
20/20 BioLabs has 13 investors. PicMii invested in 20/20 BioLabs's Convertible Note - IV funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
8/9/2025 | 12/13/2025 | PicMii | 2 Convertible Note - III, Convertible Note - IV (2025) | Equity Crowdfunding | Pennsylvania | |
2/1/2025 | 2/1/2025 | WeFunder | 1 Angel - III | Equity Crowdfunding | California | |
5/16/2020 | 12/16/2022 | 3 Angel, Angel - II (2021), Convertible Note - II (2022) | Equity Crowdfunding | California | ||
Equity Crowdfunding | California | |||||
Corporate Venture | China |
First funding | 8/9/2025 | 2/1/2025 | 5/16/2020 | ||
|---|---|---|---|---|---|
Last Funding | 12/13/2025 | 2/1/2025 | 12/16/2022 | ||
Investor | PicMii | WeFunder | |||
Rounds | 2 Convertible Note - III, Convertible Note - IV (2025) | 1 Angel - III | 3 Angel, Angel - II (2021), Convertible Note - II (2022) | ||
Board Seats | |||||
Type | Equity Crowdfunding | Equity Crowdfunding | Equity Crowdfunding | Equity Crowdfunding | Corporate Venture |
Location | Pennsylvania | California | California | California | China |
Compare 20/20 BioLabs to Competitors

Freenome operates as a biotechnology company specializing in early cancer detection within the healthcare sector. The company develops blood tests that use multiomics technology and artificial intelligence to identify cancer at its earliest and most treatable stages. It was founded in 2014 and is based in Brisbane, California.

Owlstone Medical focuses on breath analysis for disease detection within the healthcare sector. The company develops technology for discovering and validating biomarkers in breath, employing chemical analysis and sensor technology for diagnosis. Owlstone Medical's products and services are intended for academic, clinical, and pharmaceutical research partners involved in developing breath-based diagnostics. It was founded in 2004 and is based in Cambridge, United Kingdom.
OncoTAB is a biotechnology company involved in cancer diagnostics and therapeutics. The company provides a blood test, Agkura4 Personal Score, that measures levels of a tumor-associated protein to assist in the early detection of breast cancer in women with dense breast tissue. Additionally, OncoTAB develops treatments for breast and pancreatic cancers. It is based in Charlotte, North Carolina.
Liquid Genomics provides testing services for the detection of cancer gene mutations through blood-based testing within the healthcare and biotechnology sectors. The company utilizes digital PCR and allele-specific blocker PCR technologies to identify and quantify mutations in blood or tissue samples. Its services are aimed at the healthcare industry, focusing on cancer diagnostics and research. It is based in Torrance, California.

AccuraGen specializes in cancer diagnostics within the biomedical sector, focusing on the development of liquid biopsy technology. The company offers diagnostic solutions that utilize DNA and RNA sequencing for personalized medicine, allowing for non-invasive cancer detection and monitoring. AccuraGen's rolling-circle amplification technology improves genetic alteration detection, which is important for early cancer screening and minimal residual disease monitoring. It is based in Menlo Park, California.

CirculoGene Diagnostics operates within the healthcare sector, focusing on cancer detection and monitoring. The company provides genomic profiling of solid tumors at various stages, utilizing techniques like next-generation sequencing and polymerase chain reaction to analyze circulating free DNA and RNA. CirculoGene Diagnostics serves the healthcare and oncology sectors, offering products for the personalization and monitoring of cancer treatment plans. CirculoGene Diagnostics was formerly known as CirculoGene Theranostics, LLC. It was founded in 2015 and is based in Birmingham, Alabama.
Loading...

